https://orcid.org/0000-0001-6293-8211
References
- Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and Meta-analysis. PLoS One. 2017;12(5):e0177113.
- Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007;298(15):1772–1778.
- Savulescu C, Krizova P, Lepoutre A, SpIDnet group, et al. Effect of high-valency pneumococcal conjugate vaccines on invasive pneumococcal disease in children in SpIDnet countries: an observational multicentre study. Lancet Respir Med. 2017;5(8):648–656.
- Pichichero M, Kaur R, Scott DA, et al. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. Lancet Child Adolesc Health. 2018;2(8):561–568.
- Ladhani SN, Collins S, Djennad A, et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451.
- Wahl B, O'Brien KL, Greenbaum A, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15. Lancet Glob Health. 2018;6(7):e744–e757.
- Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008-2014. BMC Health Serv Res. 2018;18(1):318.
- Zhang S, Sammon PM, King I, et al. Cost of management of severe pneumonia in young children: systematic analysis. J Glob Health. 2016;6(1):010408.
- Kwambana-Adams BA, Mulholland EK, Satzke C, ISPPD group. State State-of-the-art in the pneumococcal field: Proceedings of the 11th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-11). Pneumonia (Nathan). 2020;12:2.
- Klugman KP, Rodgers GL. Time for a third-generation pneumococcal conjugate vaccine. Lancet Infect Dis. 2021;21(1):14–16.
- Food and Drug Administration. VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Prescribing Information 2021 [cited 2021 July 21]. Available from: https://www.fda.gov/media/150819/download
- Food and Drug Administration. PREVNAR 20™ (Pneumococcal 20-valent Conjugate Vaccine) Package insert 2021 [cited 2021 August 9]. Available from: https://www.fda.gov/media/149987/download
- Feikin DR, Kagucia EW, Loo JD, the Serotype Replacement Study Group, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517.
- Varghese J, Chochua S, Tran T, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. Clin Microbiol Infect. 2020;26(4):512.
- European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases: 2018. [cited 2019 October 29]. Available from: https://ecdc.europa.eu/en/surveillance-atlas-infectious-diseases.
- Pilishvili T. PCV13 effects on disease caused by serotype 3. Presentation to the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention, Atlanta, Georgia. February 28, 2019 Atlanta, Georgia: Advisory Committee on Immunization Practices; 2019. [cited 2020 June 4]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-2019-02-508.pdf.
- Rockett RJ, Oftadeh S, Bachmann NL, et al. Genome-wide analysis of Streptococcus pneumoniae serogroup 19 in the decade after the introduction of pneumococcal conjugate vaccines in Australia. Sci Rep. 2018;8(1):16969.
- Yeh SH, Gurtman A, Hurley DC, 004 Study Group, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–e505.
- Hu T, Weiss T, Owusu-Edusei K, et al. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children in the United States. J Med Econ. 2020;23(12):1653–1658.
- Hu T, Weiss T, Bencina G, et al. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries. J Med Econ. 2020;23(12):1653–1660.
- Balsells E, Dagan R, Yildirim I, et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and Meta-analysis. J Infect. 2018;77(5):368–378.
- Adam HJ, Golden AR, Karlowsky JA, et al.; Canadian Antimicrobial Resistance Alliance (CARA). Analysis of multidrug resistance in the predominant Streptococcus pneumoniae serotypes in Canada: the save study, 2011-15. J Antimicrob Chemother. 2018;73(suppl_7):vii12–vii19.